- Home
- ZYBT vs MIRM Comparison
ZYBT vs MIRM Comparison
Compare ZYBT & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYBT
- MIRM
- Stock Information
- Founded
- ZYBT 2004
- MIRM 2018
- Country
- ZYBT China
- MIRM United States
- Employees
- ZYBT N/A
- MIRM N/A
- Industry
- ZYBT
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- ZYBT
- MIRM Health Care
- Exchange
- ZYBT NYSE
- MIRM Nasdaq
- Market Cap
- ZYBT N/A
- MIRM 1.9B
- IPO Year
- ZYBT 2025
- MIRM 2019
- Fundamental
- Price
- ZYBT $10.55
- MIRM $40.00
- Analyst Decision
- ZYBT
- MIRM Strong Buy
- Analyst Count
- ZYBT 0
- MIRM 11
- Target Price
- ZYBT N/A
- MIRM $58.55
- AVG Volume (30 Days)
- ZYBT 542.9K
- MIRM 447.2K
- Earning Date
- ZYBT 01-01-0001
- MIRM 05-07-2025
- Dividend Yield
- ZYBT N/A
- MIRM N/A
- EPS Growth
- ZYBT N/A
- MIRM N/A
- EPS
- ZYBT 0.06
- MIRM N/A
- Revenue
- ZYBT $26,111,272.00
- MIRM $336,888,000.00
- Revenue This Year
- ZYBT N/A
- MIRM $29.51
- Revenue Next Year
- ZYBT N/A
- MIRM $20.27
- P/E Ratio
- ZYBT $127.92
- MIRM N/A
- Revenue Growth
- ZYBT N/A
- MIRM 80.76
- 52 Week Low
- ZYBT $3.50
- MIRM $23.14
- 52 Week High
- ZYBT $11.20
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- ZYBT N/A
- MIRM 41.05
- Support Level
- ZYBT N/A
- MIRM $38.22
- Resistance Level
- ZYBT N/A
- MIRM $40.14
- Average True Range (ATR)
- ZYBT 0.00
- MIRM 2.24
- MACD
- ZYBT 0.00
- MIRM 0.07
- Stochastic Oscillator
- ZYBT 0.00
- MIRM 48.50
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.